Sid Martin

MLM Biologics Developing Wound Infection Prevention Device for Military

MLM Biologics Inc., a graduate company of Sid Martin Biotech, has been awarded nearly $1.5 million by the US Army to develop a device that prevents infection in battlefield wounds. The device will utilize MLM Biologic's collagen processing and stabilization technologies. The focus is on preventing infection in complex, traumatic injuries in austere environments. The company plans to incorporate their proprietary technologies and proven anti-inflammatory and anti-microbial components, with potential civilian use in the future.

Alcyone Presents Preclinical Data on Gene Therapy Programs With the Center for Gene Therapy at the Abigail Wexner Research Institute (AWRI) at ASGCT 2022

Sid Martin Client Alcyone Therapeutics Inc. ("Alcyone"), a biotechnology company pioneering next-generation precision gene-based therapies for complex neurological conditions, presented preclinical data showing the Company's partnered novel adeno associated virus serotype 9 (AAV9) gene therapy vector ACTX-101 safely and effectively reactivates the inactive X chromosome in a Rett syndrome mouse model and is safe in a preliminary nonhuman primate study at the American Society of Gene & Cell Therapy (ASGCT) 25th Annual Meeting.

The Key to Life Is Learning | Dr. Ian White Founder of Neobiosis

Dr. Ian White, founder, president and chief scientific officer of UF Innovate | Sid Martin Biotech resident Neobiosis, a CDMO developing new drug applications with the FDA, producing therapeutic regenerative medicine products for human use, is featured on The Huxley Morton Podcast.

AGTC Licenses Promoter Technology to SparingVision SAS

UF startup and UF Innovate | Sid Martin Biotech alum Applied Genetic Technologies Corporation (AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare diseases, announced a licensing agreement that provides its proprietary cone-specific promoter technology to SparingVision SAS, a genomic medicine company developing vision-saving treatments for ocular diseases.